3  Receptors and Intracellular Signaling

3.1 GLP-1R and GIPR: class B1 GPCRs

The GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR) are both class B1 (secretin receptor family) G protein-coupled receptors (GPCRs). The same family includes the glucagon receptor, the GLP-2 receptor, the PTH receptor, the calcitonin receptor, and others.

Class B1 GPCRs have a large extracellular domain (ECD) and a seven-transmembrane domain (TMD), and peptide ligands are thought to bind in “two steps”.

flowchart LR
  S1["① The peptide's C-terminal part<br/>binds the ECD<br/>(determines affinity and selectivity)"] --> S2["② The peptide's N-terminal part<br/>enters the TMD pocket<br/>(activates the receptor)"]
  S2 --> S3["Conformational change of the receptor<br/>→ Gαs activation"]

This two-step model makes the DPP-4 story of Chapter 2 easy to understand. What DPP-4 cuts off are the two N-terminal residues, i.e., the part needed to activate the receptor. Even if the cleaved GLP-1(9-36) and GIP(3-42) can still bind the ECD to some extent, they can barely activate the receptor.

3.1.1 Where are the receptors?

Tissue GLP-1R GIPR
Pancreatic β-cells ◎ ◎
Pancreatic α-cells △ (few) ◎
Pancreatic δ-cells ○ ○
Brain (hypothalamus, brainstem) ◎ ○
Gastric and intestinal nerves ◎
Vagal afferent fibers ◎
Adipose tissue △ ◎
Heart, blood vessels ○ (sinoatrial node, etc.)
Kidney ○
Bone ○

The differences in receptor distribution are the basis for the differences in action covered in Chapters 4 and 5.

3.2 What happens inside the β-cell?

3.2.1 Prerequisite: insulin secretion by glucose itself (triggering pathway)

To understand the action of incretins, we first need to understand how glucose itself causes insulin release.

flowchart TB
  G["Blood glucose↑"] --> GLUT["Glucose enters the β-cell<br/>via GLUT2 (rodents)/GLUT1 (humans)"]
  GLUT --> GK["Glucokinase → glycolysis → mitochondria"]
  GK --> ATP["ATP/ADP ratio↑"]
  ATP --> KATP["K_ATP channels close"]
  KATP --> Dep["Membrane depolarization"]
  Dep --> VDCC["Voltage-gated Ca²⁺ channels open"]
  VDCC --> Ca["Intracellular Ca²⁺↑"]
  Ca --> Exo["Exocytosis of insulin granules"]

This is the triggering pathway. The key point is that sulfonylurea (SU) drugs close K_ATP channels directly, independently of glucose metabolism, so they cause insulin release even when blood glucose is low (→ risk of hypoglycemia).

3.2.2 Incretins “amplify”

GLP-1 and GIP amplify this triggering pathway.

flowchart TB
  Inc["GLP-1 / GIP"] --> R["GLP-1R / GIPR"]
  R --> Gs["Gαs"]
  Gs --> AC["Adenylyl cyclase"]
  AC --> cAMP["cAMP↑"]
  cAMP --> PKA["PKA"]
  cAMP --> Epac["Epac2<br/>(cAMP-GEFII)"]
  PKA --> E1["Promotes K_ATP channel closure<br/>Enhances Ca²⁺ channel currents"]
  PKA --> E2["Ca²⁺ release from the ER<br/>(Ca²⁺-induced Ca²⁺ release)"]
  Epac --> E3["Promotes docking and<br/>exocytosis of insulin granules<br/>(Rap1, Rim2, Piccolo)"]
  PKA --> E4["CREB → insulin gene transcription↑<br/>β-cell survival signals"]
  E1 --> Out["Insulin secretion↑<br/>(but only when blood glucose is high)"]
  E2 --> Out
  E3 --> Out

The main pathway is an increase in Gαs → adenylyl cyclase → cAMP, downstream of which two effectors act.

  • PKA (protein kinase A): phosphorylates ion channels and the exocytotic machinery and enhances Ca²⁺ signaling. In the long term, it promotes insulin gene transcription and β-cell survival via CREB
  • Epac2 (cAMP-GEFII): promotes exocytosis of insulin granules independently of PKA

3.2.3 Why “glucose-dependent”?

GLP-1 and GIP increase insulin secretion only when blood glucose is high. This is why incretin-based drugs rarely cause hypoglycemia on their own.

An intuitive explanation:

  • The cAMP pathway is not “the accelerator” but “a mechanism that makes the accelerator more effective”
  • When the accelerator (glucose metabolism → ATP↑ → K_ATP closure → depolarization → Ca²⁺ influx) is not pressed, i.e., during hypoglycemia, there is nothing to amplify
  • In fact, in humans, when blood glucose falls below roughly 70–80 mg/dL, the insulinotropic action of GLP-1 almost disappears
ImportantKey points
  • SU drugs = pull the trigger regardless of blood glucose → can cause hypoglycemia
  • Incretins = amplification when the trigger has been pulled → rarely cause hypoglycemia on their own
  • However, the risk of hypoglycemia rises when combined with SU drugs or insulin (because the trigger is always being pulled)

In Chapter 7, we will check this difference on a graph.

3.3 The receptor’s “aftermath”: β-arrestin and internalization

When a GPCR is activated, it is phosphorylated by GRKs and β-arrestin binds, leading to

  • termination (desensitization) of G protein signaling
  • uptake of the receptor into the cell (internalization)

This is a mechanism that protects the cell from sustained stimulation, but with long-acting drugs it may lead to a weakening of the effect (tachyphylaxis).

3.3.1 Biased agonism

Even when binding the same receptor, how strongly a ligand elicits G protein signaling versus β-arrestin recruitment differs from ligand to ligand. This bias is called biased agonism.

It has been reported that the GIP/GLP-1 receptor agonist tirzepatide, at GLP-1R,

  • preserves cAMP production, while
  • recruiting β-arrestin only weakly, so receptor internalization is less likely

—— i.e., it has a cAMP-biased profile. This may contribute to sustained insulin secretion in β-cells (Chapter 6).

3.4 Characteristics of GIPR signaling

GIPR basically uses the same Gαs → cAMP pathway as GLP-1R. The differences are:

  • It is highly expressed in α-cells as well and stimulates glucagon secretion (Chapter 4)
  • It is expressed in adipocytes and is involved in lipid metabolism (Chapter 5)
  • In the hyperglycemic state of type 2 diabetes, reduced expression and desensitization of β-cell GIPR occur, blunting the response to GIP. Because the response to GIP partly recovers when blood glucose is normalized, this reduced response is thought to be at least partly reversible

3.5 Summary

  • GLP-1R and GIPR are class B1 GPCRs. The peptide’s N-terminus is essential for receptor activation (which is why cleavage by DPP-4 inactivates them)
  • The main pathway is Gαs → cAMP → PKA / Epac2
  • Incretins only amplify glucose-induced insulin secretion, so their action is glucose-dependent
  • There is desensitization and internalization by β-arrestin, and the bias differs between ligands